BCL2L1 and cancer: Overexpression of STAT3 has been linked to cancer, and CPT treatment slows the growth of cancer by blocking STAT3 by selectively decreasing STAT3 Tyr705 phosphorylation and its downstream target proteins, which include Bcl-xL, survivin, and cyclin D1 in prostate cancer [72].